Vanguard Capital Management’s Stoke Therapeutics STOK Stock Holding History
Bought
Maintained
Sold
Other funds holding STOK
LCM
Vanguard Capital Management's STOK Position: Q3 2026 in Review
Vanguard Capital Management increased its Stoke Therapeutics (STOK) stake by 5.7% in Q3 2026, buying an estimated $4.42M and bringing the position to 2,733,417 shares worth $71.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1717.
Vanguard Capital Management first reported a position in STOK in Q1 2026 and has held it in 3 quarters since. The position peaked at $84.6M in Q2 2026. 185 funds tracked by Wall St. Rank hold STOK as of Q3 2026.
- Vanguard Capital Management held 2,733,417 shares of Stoke Therapeutics worth $71.1M as of Q3 2026.
- Vanguard Capital Management bought 146,480 Stoke Therapeutics shares in Q3 2026, an estimated $4.42M.
- Stoke Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1717 holding.
- Vanguard Capital Management first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Stoke Therapeutics position peaked at $84.6M in Q2 2026.
- 185 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.